Inhibitor for Ebola virus

A technology of Ebola virus and disease, applied in the field of medicine, can solve problems such as threats to the personal safety of researchers and restrictions on the development of effective drugs

Inactive Publication Date: 2018-03-13
NAT INST FOR FOOD & DRUG CONTROL
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In particular, since the biosafety level of Ebola virus is level 4, relevant research on it needs to be carried out in a level 4 laboratory, which not only poses a huge threat to the personal safety of researchers, but also greatly limits the development of effective drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibitor for Ebola virus
  • Inhibitor for Ebola virus
  • Inhibitor for Ebola virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0058] Embodiment 1. Construction of pseudovirus

[0059] 1.1 Antiviral Drug Screening Principle Based on Pseudovirus

[0060] The envelope protein on the virus (for example, the envelope protein of Ebola virus) is responsible for recognizing the receptor on the surface of the target cell to initiate the process of adsorption and penetration, thereby invading the cell. Furthermore, the phenotypic mixing that occurs when two viruses co-infect a cell suggests that the envelope of one virus can be integrated on the particle surface of a different virus. Based on the above two points, a new technology—pseudovirus technology has been developed in the study of the process of virus invasion into cells and its tissue tropism and receptors.

[0061] The current pseudovirus refers to a retrovirus that can integrate the envelope glycoprotein of another different type of virus to form an envelope with an exogenous virus, and the genome maintains the genomic characteristics of the retro...

Embodiment 2

[0079] Embodiment 2.EBOV-10 is to the evaluation of the inhibitory activity of Ebola pseudovirus

[0080] In this embodiment, the Ebola virus inhibitory activity of EBOV-10 (national standard product of dicyclomine hydrochloride, provided by China National Institutes for Food and Drug Control Standard Materials) was evaluated by using the above-mentioned Ebola pseudovirus.

[0081] Since the pseudovirus backbone plasmid pSG3Δenv.cmvFluc used in the present invention is derived from HIV, in order to exclude the possibility that the drug inhibits the pseudovirus by preventing the reverse transcription process of the backbone HIV, the present invention utilizes the Ebola pseudovirus primary screening drug while , using a chimeric pseudovirus containing the membrane protein of vesicular stomatitis virus (VSV) for re-screening to exclude false positives. Calculate the ratio of the drug to the 50% inhibitory concentration (IC50) of the VSV membrane protein chimeric pseudovirus and t...

Embodiment 3

[0094] Example 3. Cytotoxicity evaluation of EBOV-10

[0095] In the present embodiment, the influence of EBOV-10 drug (dicyclomine hydrochloride national standard product, provided by the standard material of China Institute for Food and Drug Control) on cell activity is evaluated by ATP quantitative determination, and its detection principle is as follows:

[0096] ATP is an indicator of metabolism in living cells, using Luminescence method cell viability detection kit, through the quantitative determination of ATP to detect the number of living cells in the culture after the action of drugs and cells, the cell lysis and the luminescent signal produced are proportional to the amount of ATP present, and the amount of ATP is directly related to the culture Proportional to the number of cells in . The 50% cytotoxic concentration (CC50) of the drug was calculated by the effect of the drug on the ATP luminescent signal in the cells. Calculate the ratio of the 50% cytotoxic con...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicines. In particular, the invention relates to application of a bicyclic amine compound having a structure shown by formula (I) in prevention and/ortreatment of Ebola virus infections or diseases (e.g., Ebola hemorrhagic fever) caused by the Ebola virus infections. The present application also relates to application of a bicyclic amine compoundhaving a structure shown by formula (I) in preparation of pharmaceutical compositions for preventing and/or treating Ebola virus infections or the diseases (e.g., Ebola hemorrhagic fever) caused by the Ebola virus infections.

Description

technical field [0001] The invention belongs to the technical field of medicine. In particular, the present invention relates to the use of bicyclic amine compounds having a structure of formula (I) for preventing and / or treating Ebola virus infection or diseases caused by Ebola virus infection (for example, Ebola hemorrhagic fever) use. The present application also relates to a bicyclic amine compound having a structure of formula (I) for the preparation of a medicament for preventing and / or treating Ebola virus infection or diseases caused by Ebola virus infection (for example, Ebola hemorrhagic fever) Use of the composition. [0002] Background technique [0003] Ebola hemorrhagic fever (EBHF) is the deadliest viral hemorrhagic fever in the world today. Symptoms of infected people are very similar to those of Marburg virus, which belongs to the same family of fibroviridae, including nausea, vomiting, diarrhea, skin color changes, body aches, Hemorrhage, extracorpore...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/215A61P31/14
CPCA61K31/215
Inventor 王佑春谢会雷山刘强黄维金邱香果李玉华
Owner NAT INST FOR FOOD & DRUG CONTROL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap